SCHEMBL21999079

SCHEMBL21999079

O=C(O)CCC(O)NCC(CC(=O)O)S(=O)(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 6/20 0.38
TET2 Q6N021 3/20 0.36
KDM4A O75164 2/20 0.36
KDM4C Q9H3R0 2/20 0.36
KDM2A Q9Y2K7 2/20 0.36
TET3 O43151 1/20 0.36
CYP1A2 P05177 2/20 0.35
DPP4 P27487 1/20 0.33
DPP8 Q6V1X1 1/20 0.33
DPP9 Q86TI2 1/20 0.33
RIMKLA Q8IXN7 1/20 0.32
NAALAD2 Q9Y3Q0 1/20 0.32
SLC22A6 Q4U2R8 1/20 0.32
CTSC P53634 1/20 0.32
GABRP O00591 2/20 0.31
GABRD O14764 2/20 0.31
GABRA1 P14867 2/20 0.31
GABRB1 P18505 2/20 0.31
GABRG2 P18507 2/20 0.31
GABRB3 P28472 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10932851 0.81 FOLH1 (0.46) FOLH1TET2KDM4AKDM4CKDM2A
SCHEMBL28220537 0.79 FOLH1 (0.45) FOLH1TET2KDM4AKDM4CKDM2A
SCHEMBL9402802 0.79 FOLH1 (0.45) FOLH1TET2KDM4AKDM4CKDM2A
SCHEMBL28221122 0.79 FOLH1 (0.45) FOLH1TET2KDM4AKDM4CKDM2A
SCHEMBL29040544 0.76 ECE1 (0.33) FOLH1TDP1APEX1
SCHEMBL11927646 0.75 PHF8 (0.38) FOLH1KDM2ATDP1APEX1
SCHEMBL12226844 0.74 TET2 (0.44) FOLH1TET2KDM4AKDM4CKDM2A
SCHEMBL11931677 0.73
SCHEMBL3142793 0.73 TDP1 (0.48) FOLH1CYP1A2SLC22A6TDP1APEX1
SCHEMBL3752305 0.72 TET2 (0.48) FOLH1TET2KDM4AKDM4CKDM2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11046762-B2 Cross-linkers and their uses IMMUNOGEN, INC. (US) 2021-06-29 US disclosed
US-20200148764-A1 CROSS-LINKERS AND THEIR USES IMMUNOGEN, INC. 2020-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200148764-A1 CROSS-LINKERS AND THEIR USES MTCL3, DCLRE1A, PCNA FOLH1 49/4885TET2 4574/4885KDM4A 3266/4885
US-11046762-B2 Cross-linkers and their uses MTCL3, DCLRE1A, PCNA FOLH1 49/4885TET2 4574/4885KDM4A 3266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.